Biodexa Pharmaceuticals (BDRX) Cash from Financing Activities (2015 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Cash from Financing Activities of -$91488.4 for Q4 2022, up 5.16% sequentially from -$96464.6 in Q3 2022, and up 16.21% YoY from -$78726.2 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Cash from Financing Activities (2015 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at -$91488.4 in Q4 2022.
- Quarterly Cash from Financing Activities rose 16.21% year-over-year to -$91488.4 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$409690.2 (down 153.11% YoY) and the FY2025 annual result came in at $17.2 million, up 56.53% from the prior year.
- Cash from Financing Activities improved to -$91488.4 in Q4 2022 per BDRX's latest filing, from -$96464.6 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $15.7 million in Q4 2019 and troughed at -$112548.3 in Q3 2021.
- A 5-year average of $2.0 million and a median of -$50247.9 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2019 and 2021: Cash from Financing Activities soared 174729.86% in 2019, then sank 123.21% in 2021.
- Over 5 years, Cash from Financing Activities stood at -$9007.4 in 2018, then jumped by 174729.86% to $15.7 million in 2019, then tumbled by 96.77% to $508373.6 in 2020, then tumbled by 121.48% to -$109188.9 in 2021, then gained by 16.21% to -$91488.4 in 2022.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$91488.4, -$96464.6, and -$109188.9 for Q4 2022, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -91,488.41 |
| Dec 31, 2022 | -91,488.41 |
| Sep 14, 2022 | -96,464.63 |
| Sep 14, 2022 | -96,464.63 |
| Dec 31, 2021 | -109,188.86 |
| Dec 31, 2021 | -109,188.86 |
| Sep 17, 2021 | -112,548.28 |
| Sep 17, 2021 | -112,548.28 |
| Dec 31, 2020 | 508,373.64 |
| Dec 31, 2020 | 508,373.64 |
| Sep 10, 2020 | 484,822.94 |
| Sep 10, 2020 | 484,822.94 |
| Dec 31, 2019 | 15.73 Mn |
| Dec 31, 2019 | 15.73 Mn |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2015 | -332,330.43 |
| Dec 31, 2015 | -332,330.43 |